Details for Patent: 8,536,130
✉ Email this page to a colleague
Which drugs does patent 8,536,130 protect, and when does it expire?
Patent 8,536,130 protects NUCYNTA ER and is included in one NDA.
Protection for NUCYNTA ER has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighteen patent family members in twelve countries.
Summary for Patent: 8,536,130
| Title: | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain |
| Abstract: | Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy. |
| Inventor(s): | Christoph; Thomas (Aachen, DE), Friderichs; Elmar (Stolberg, DE), Koegel; Babette-Yvonne (Langerwehe-Hamich, DE), Meen; Murielle (Ayguesvives, FR) |
| Assignee: | Gruenenthal GmbH (Aachen, DE) |
| Application Number: | 12/850,208 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,536,130 |
|
Patent Claim Types: see list of patent claims | Use; |
Recent additions to Drugs Protected by US Patent 8,536,130
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE | 200533 | Aug 25, 2011 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-1276 | MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 8,536,130
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-001 | Aug 25, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-002 | Aug 25, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-003 | Aug 25, 2011 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,536,130
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 10 2007 012 165 | Mar 12, 2007 |
International Family Members for US Patent 8,536,130
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2680771 | ⤷ Sign Up | |||
| Cyprus | 1115455 | ⤷ Sign Up | |||
| Germany | 102007012165 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
